Advisory Alpha LLC Purchases 492 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Advisory Alpha LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 18.2% in the 4th quarter, Holdings Channel reports. The firm owned 3,189 shares of the medical research company’s stock after buying an additional 492 shares during the quarter. Advisory Alpha LLC’s holdings in IQVIA were worth $627,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at approximately $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the 3rd quarter valued at $28,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Assetmark Inc. increased its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, UMB Bank n.a. raised its position in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research reports. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Bank of America reduced their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Finally, Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Performance

IQVIA stock opened at $205.37 on Thursday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The stock’s 50 day simple moving average is $199.53 and its two-hundred day simple moving average is $221.30. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $37.27 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 2.14 and a beta of 1.48.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.